INTRODUCTION
Metastases to the bone occur in up to 75% of patients with breast and prostate cancer and can severely affect quality of life. This Brief examines
trends in the bone metastases market for both prostate and breast cancer, the potential of the drugs for cancer-related osteoporosis and what
pharmaceutical companies need to do to consolidate their positions in the market.
SCOPE OF THE REPORT
- Overview of treatment of bone metastases in breast and prostate cancer
- Potential of bisphosphonates in the osteoporosis market
- Clinical application of bisphosphonates in adjuvant setting
- Opinions from leading physicians in the field of bisphosphonates
REPORT HIGHLIGHTS
Novartis' Zometa will overtake Aredia as the gold standard treatment for bone metastases imminently
The use of Zometa in combination with anti-aromatase agents will be the key to Novartis' expansion in the bone metastases market
There is significant potential of bisphosphonates in the treatment of hormonal therapy-induced osteoporosis, especially in the prostate cancer
market
KEY REASONS TO BUY THIS REPORT
- Predict the commercial potential of bisphosphonates for osteoporosis to determine the viability of entry into the market
- Determine the possible clinical applications of bisphosphonates and maximize the full market potential of your product
- Enhance your commercial positioning by understanding the cost-effectiveness of bisphosphonate therapy for bone metastases
View Cart
